Patents Issued in May 12, 2020
-
Patent number: 10646567Abstract: The present invention describes combination treatment comprising a PD-1 axis binding antagonist and a MEK inhibitor and methods for use thereof, including methods of treating conditions where enhanced immunogenicity is desired such as increasing tumor immunogenicity for the treatment of cancer.Type: GrantFiled: June 28, 2017Date of Patent: May 12, 2020Assignee: Genentech, Inc.Inventors: Heather Maecker, Bryan Irving
-
Patent number: 10646568Abstract: Disclosed are methods and compositions for targeting antibodies to amyloid deposits. For example, amyloid-reactive peptides that bind amyloid deposits are administered to a subject. Antibodies to the amyloid-reactive peptides are then administered to the subject. Upon administration of the antibodies, the amyloid-reactive peptides bind the antibodies and thus pre-target the antibodies to the amyloid deposits. In other examples, an amyloid-reactive fusion peptide contains an epitope of a known antibody. When the fusion peptide is administered to a subject, the fusion peptide binds amyloids in the subject. Administration to the subject of the known antibody that binds the epitope of the fusion peptide then targets the antibody to the amyloid deposit to which the fusion peptide is bound.Type: GrantFiled: July 16, 2018Date of Patent: May 12, 2020Assignee: UNIVERSITY OF TENESSEE RESEARCH FOUNDATIONInventors: Jonathan S Wall, Stephen J Kennel, James S Foster
-
Patent number: 10646569Abstract: The present disclosure, among other things, provides low-viscosity, high concentration therapeutic protein agent formulations.Type: GrantFiled: June 20, 2017Date of Patent: May 12, 2020Assignee: Bhami's Research Laboratory, Pvt. Ltd.Inventor: Bhami Shenoy
-
Patent number: 10646570Abstract: Photodynamic therapy systems comprising a nanoparticle that emits electromagnetic radiation having a first wavelength when irradiated with electromagnetic radiation, a photosensitizer which absorbs electromagnetic radiation of said first wavelength and a biocompatible mesoporous material are disclosed herein. In some examples, the photodynamic therapy system comprises a core comprising the nanoparticle, a first shell comprising the biocompatible mesoporous material, and a photosensitizer embedded in the first shell. Upon irradiation by, for example, X-rays, the nanoparticle can function as a transducer, converting X-ray photons to visible photons, and in turn, activating the photosensitizers. Methods of using the photodynamic therapy system are also disclosed.Type: GrantFiled: June 18, 2015Date of Patent: May 12, 2020Assignee: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC.Inventors: Jin Xie, Hongmin Chen, Geoffrey D. Wang
-
Patent number: 10646571Abstract: Concentrated, low-viscosity, low-volume liquid pharmaceutical formulations of proteins have been developed. Such formulations can be rapidly and conveniently administered by subcutaneous or intramuscular injection, rather than by lengthy intravenous infusion. These formulations include low-molecular-weight and/or high-molecular-weight proteins, such as mAbs, and viscosity-lowering agents that are typically bulky polar organic compounds, such as many of the GRAS (US Food and Drug Administration List of compounds generally regarded as safe) and inactive injectable ingredients and FDA approved therapeutics.Type: GrantFiled: February 23, 2018Date of Patent: May 12, 2020Assignee: Eagle Biologics, Inc.Inventors: Alyssa M. Larson, Kevin Love, Alisha K. Weight, Alan Crane, Robert S. Langer, Alexander M. Klibanov
-
Patent number: 10646572Abstract: The present invention provides for a stabilized biodegradable polymeric composition useful as a controlled release delivery system for peptide agents. The compositions of the present invention comprise a) a beneficial salt of a luteinizing hormone releasing hormone (LHRH) analogue formed with a strong acid that minimizes or prevents the interaction/reaction between the LHRH and the polymer in an organic solution; b) a biodegradable polymer; c) a pharmaceutically acceptable organic solvent; and d) optionally one or more excipients. The present invention also relates to a method of manufacturing and a method of use thereof.Type: GrantFiled: April 5, 2019Date of Patent: May 12, 2020Assignee: Foresee Pharmaceuticals Co., Ltd.Inventors: Yuhua Li, Benjamin Chien
-
Patent number: 10646573Abstract: Provided is a composition for hot melt extrusion including a drug and hypromellose acetate succinate (HPMCAS) having a hydroxypropoxy molar substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6. Further, provided is a method for producing a hot melt extrudate including the step of hot melt-extruding a composition for hot melt extrusion including a drug and hypromellose acetate succinate having a molar hydroxypropoxy substitution of 0.40 or more and a mole ratio of an acetyl group to a succinyl group of less than 1.6, at a hot melt temperature of not lower than a melting temperature of the hypromellose acetate succinate or of not lower than a temperature at which both the hypromellose acetate succinate and the drug are melted.Type: GrantFiled: June 3, 2014Date of Patent: May 12, 2020Assignee: SHIN-ETSU CHEMICAL CO., LTD.Inventors: Shogo Warashina, Fumie Kusaki, Sakae Obara, Kazuki Kikuchi, Naosuke Maruyama
-
Patent number: 10646574Abstract: Provided herein are compositions and methods for preparing intraarticular formulations comprising biocompatible pharmaceutical agents and use thereof in the treatment of diseases, such as degenerative bone diseases, including osteoarthritis of the knee, hip, or other joints, and similar chronic or acute destructive arthropathies resulting from autoimmune disorders or infectious disease.Type: GrantFiled: July 20, 2015Date of Patent: May 12, 2020Assignee: Board of Regents, The University of Texas SystemInventors: Jeffrey J. Tarrand, Borje S. Andersson
-
Patent number: 10646575Abstract: This invention provides heterocyclic compounds that bind to E3 Ubiquitin Ligase (typically through cereblon) (“Degrons”), which can be used as is or linked to a Targeting Ligand for a selected Target Protein for therapeutic purposes and methods of use and compositions thereof as well as methods for their preparation.Type: GrantFiled: November 9, 2018Date of Patent: May 12, 2020Assignee: C4 Therapeutics, Inc.Inventors: Andrew J. Phillips, Chris G. Nasveschuk, James A. Henderson, Yanke Liang, Mark E. Fitzgerald, Minsheng He, Ryan E. Michael
-
Patent number: 10646576Abstract: A composition including an immunostimulating RNA molecule in a dication containing solution wherein the RNA includes a chemical modification which is toxic to cancer or tumor cells. Pharmaceutical compositions incorporate the immunostimulating RNA with tumor cytotoxicity. Methods for treating cancer and tumors use the solution of the immunostimulating RNA with tumor cytotoxicity.Type: GrantFiled: October 12, 2016Date of Patent: May 12, 2020Assignee: spRNA GmbHInventor: Steve Pascolo
-
Patent number: 10646577Abstract: Disclosed herein, inter alia, are compounds and methods of using the same for modulating the activity of mTORC1.Type: GrantFiled: September 10, 2018Date of Patent: May 12, 2020Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Kevan Shokat, Masanori Okaniwa
-
Patent number: 10646578Abstract: Polymeric reagents are provided comprising a moiety of atoms arranged in a specific order, wherein the moiety is positioned between a water-soluble polymer and a reactive group. The polymeric reagents are useful for, among other things, forming polymer-active agent conjugates. Related methods, compositions, preparations, and so forth are also provided.Type: GrantFiled: January 31, 2018Date of Patent: May 12, 2020Assignee: Nektar TherapeuticsInventors: J. Milton Harris, Antoni Kozlowski, Samuel P. McManus, Michael D. Bentley, Stephen A. Charles
-
Patent number: 10646579Abstract: Provided is a composition comprising an RNAi molecule which suppresses expression of CHST15 gene and successfully used for less invasive administration. A complex comprising an RNAi molecule which suppresses expression of CHST15 gene and an N-ace.Type: GrantFiled: November 2, 2016Date of Patent: May 12, 2020Assignee: TME THERAPEUTICS INC.Inventor: Hiroyuki Yoneyama
-
Patent number: 10646580Abstract: This disclosure relates to conjugates for targeting bacteria and related uses. In certain embodiments, the disclosure relates to methods of transferring a molecule of interest into bacteria comprising mixing bacteria with a non-naturally occurring conjugate under conditions such that the conjugate is transported across the bacterial cell wall. Typically, the conjugate comprises an oligosaccharide and a molecule of interest. In certain embodiments, the molecule of interest may be a tracer or an antibiotic.Type: GrantFiled: November 2, 2017Date of Patent: May 12, 2020Assignees: Emory University, Georgia Tech Research Corporation, Georgia State University Research Foundation, Inc.Inventors: Niren Murthy, Eric Seth Gilbert, Xinghai Ning, Mark Goodman, Bryan Stubblefield
-
Patent number: 10646581Abstract: Described herein are prostate specific membrane antigen (PSMA) binding conjugates that are useful for delivering therapeutic, diagnostic and imaging agents. Also described herein are pharmaceutical composition containing them and methods of using the conjugates and compositions. Also described are processes for manufacture of the conjugates and the compositions containing them.Type: GrantFiled: May 25, 2018Date of Patent: May 12, 2020Assignee: Purdue Research FoundationInventors: Philip S. Low, Sumith A. Kularatne
-
Patent number: 10646582Abstract: Described herein are block copolymers, and methods of making and utilizing such copolymers. The described block copolymers are disruptive of a cellular membrane, including an extracellular membrane, an intracellular membrane, a vesicle, an organelle, an endosome, a liposome, or a red blood cell. Preferably, in certain instances, the block copolymer disrupts the membrane and enters the intracellular environment. In specific examples, the block copolymer is endosomolytic and capable of delivering an oligonucleotide (e.g., an mRNA) to a cell. Compositions comprising a block copolymer and an oligonucleotide (e.g., an mRNA) are also disclosed.Type: GrantFiled: November 30, 2017Date of Patent: May 12, 2020Assignee: Genevant Sciences GmbHInventors: Sean D. Monahan, Michael S. DeClue, Pierrot Harvie, Russell N. Johnson, Amber E. Paschal, Mary G. Prieve, Debashish Roy, Charbel Diab, Michael E. Houston, Jr., Anna Galperin, Maher Qabar
-
Patent number: 10646583Abstract: Antibody drug conjugates (ADC's) that bind to CD37 protein and variants thereof are described herein. CD37 exhibits a distinct and limited expression pattern in normal adult tissue(s), and is aberrantly expressed in the cancers listed in Table I. Consequently, the ADC's of the invention in some embodiments provide a therapeutic composition for the treatment of cancer.Type: GrantFiled: February 8, 2018Date of Patent: May 12, 2020Assignee: AGENSYS, INC.Inventors: Daniel Sousa Pereira, Faisal Hayat Malik, Josh Snyder, Leslie Renee Butterworth, Ssucheng Jeff Hsu, Peng Yang, Claudia Isabel Guevara
-
Patent number: 10646584Abstract: A compound which is either A: or B: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.Type: GrantFiled: May 14, 2019Date of Patent: May 12, 2020Assignee: MEDIMMUNE LIMITEDInventor: Philip Wilson Howard
-
Patent number: 10646585Abstract: Hydrophilic linkers are useful for linking drugs to cell-binding ligands in ligand-drug conjugates, such as antibody-drug conjugates. The ligand-drug conjugate includes a cell-binding ligand capable of binding to a particular cell population, and a drug connected to the ligand by a hydrophilic linker. The hydrophilic linker includes one or more hydrophilic groups that render the linker hydrophilic. The hydrophilic linker may also include functional groups at the two termini for coupling to the drug and the cell-binding ligand respectively.Type: GrantFiled: December 19, 2018Date of Patent: May 12, 2020Assignee: HANGZHOU DAC BIOTECH CO., LTD.Inventors: Sanxing Sun, Robert Yongxin Zhao, Xing Li, Huihui Guo, Junxiang Jia, Hongsheng Xie, Xiaomai Zhou, Yuanyuan Huang, Qingliang Yang, Xiaotao Zhuo, Hangbo Ye, Shun Gai, Lan Qu, Wenjun Li, Chen Lin
-
Patent number: 10646586Abstract: The present invention concerns the preparation and the therapeutic use of aqueous solutions of Progesterone or Testosterone, complexed with hydroxypropyl-3-cyclodextrin (HP?CD) that are suitable for oral administration. The solutions are characterised by a specific molar ratio between HP?CD and the hormones such as to ensure high hormone plasma levels, following oral administration, thanks to the optimisation of their solubility, permeability, metabolic stability and ultimately, bio availability. The formulation object of the present patent makes it possible to achieve effective plasma concentrations following oral administration of lower doses of hormone with respect to oral formulations currently on the market (e.g. Prometrium, Andriol) to the advantage of greater safety and compliance of the patients.Type: GrantFiled: November 22, 2013Date of Patent: May 12, 2020Assignee: ALTERGON S.A.Inventors: Alberto Bernareggi, Nadia Puppini, Alessandro Nencioni
-
Patent number: 10646587Abstract: Recombinant adenoviral vectors, immunogenic compositions thereof and their use in medicine, and methods for generating recombinant adenoviral vectors are provided. In particular, the an adenovirus vector having a capsid derived from chimpanzee adenovirus AdY25, wherein the capsid encapsidates a nucleic acid molecule comprising an exogeneous nucleotide sequence of interest are provided.Type: GrantFiled: June 20, 2017Date of Patent: May 12, 2020Assignee: OXFORD UNIVERSITY INNOVATION LIMITEDInventors: Matthew Douglas James Dicks, Matthew Guy Cottingham, Adrian Vivian Sinton Hill, Sarah Gilbert
-
Patent number: 10646588Abstract: Disclosed are adeno-associated virus (AAV) vectors comprising a nucleotide sequence encoding RP2 or RPGR-ORF15 and related pharmaceutical compositions. Also disclosed are methods of treating or preventing X-linked retinitis pigmentosa, increasing photoreceptor number in a retina of a mammal, and increasing visual acuity of a mammal using the vectors and pharmaceutical compositions.Type: GrantFiled: March 11, 2016Date of Patent: May 12, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Zhijian Wu, Anand Swaroop, Suddhasil Mookherjee, Suja Hiriyanna
-
Patent number: 10646589Abstract: The present invention provides a composition which comprises the following Thyroid Stimulating Hormone Receptor (TSHR) peptides: (i) all or part of the amino acid sequence KKKKYVSIDVTLQQLESHKKK (SEQ ID NO: 1), or a part thereof, or a sequence having at least 60% sequence identity to SEQ ID NO:1; and (ii) all or part of the amino acid sequence GLKMFPDLTKVYSTD (SEQ ID NO: 2), or a part thereof, or a sequence having at least 60% sequence identity to SEQ ID NO:2. The present invention also relates to the use of such a composition for the prevention or suppression of activating autoantibody formation in Graves' disease.Type: GrantFiled: December 23, 2015Date of Patent: May 12, 2020Assignee: APITOPE INTERNATIONAL NVInventors: Lotta Jansson, Keith Martin, David Wraith, Andrea Jahraus, Kathleen Vrolix
-
Patent number: 10646590Abstract: The present invention includes methods for transferring a multigenic phenotype to a cell by transfecting, preferably by phototransfection, and locally transfecting a cell or a cellular process with a laser while the cell is bathed in a fluid medium comprising two or more nucleic acids, thereby introducing the nucleic acid into the interior of the cell. Expression of the nucleic acids results in a multigenic phenotype in the transfected cell.Type: GrantFiled: December 12, 2006Date of Patent: May 12, 2020Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIAInventors: James Eberwine, Philip G. Haydon, Jai-Yoon Sul, Hajime Takano, Chia-Wen Kitty Wu, Fanyi Zeng
-
Patent number: 10646591Abstract: Disclosed are imaging agents having the following Formula I: wherein F is a near infrared fluorophore, S is an enzymatically cleavable oligopeptide, Q is a fluorescence quencher molecule, and M is a moiety selected from the group consisting of PEG or derivative thereof and a targeting ligand, and wherein F, Q and M are linked to separate amino acids of the enzymatically cleavable oligopeptide. Compositions comprising such compounds, as well as methods of use, methods of identifying a cell or a population of cells in vivo expressing a protease of interest, and methods of treating a disease through imaging are also disclosed.Type: GrantFiled: October 28, 2016Date of Patent: May 12, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Xiaoyuan Chen, Seulki Lee, Lei Zhu
-
Patent number: 10646592Abstract: This invention relates to, in part, methods and compositions that are useful for the diagnosis, treatment, or prevention of a blinding eye disease, including in the discovery of drugs that are efficacious against these diseases. Diseases include, for example, age related macular degeneration and reticular pseudodrusen disease, and the methods described herein include, for example, the method named delayed near infrared analysis (DNIRA).Type: GrantFiled: February 19, 2019Date of Patent: May 12, 2020Assignee: Translatum Medicus Inc.Inventor: Shelley Romayne Boyd
-
Patent number: 10646593Abstract: The present disclosure provides activatable and detectable membrane-interacting peptides that, following activation, can interact with phospholipid bilayers, such as cell membranes. The present disclosure also provides methods of use of such compounds. The compounds of the present disclosure are of the general structure X1a-A-X2-Z-X1b, where A is a membrane-interacting peptide region having a plurality of nonpolar hydrophobic amino acid residues that, following separation from portions Z, is capable of interaction with a phospholipid bilayer; Z is an inhibitory peptide region that can inhibit the activity of portion A; X2 is a cleavable linker that can be cleaved to release cleavage products from the compound; and X1a and X1b are optionally-present chemical handles that facilitate conjugation of various cargo moieties to the compound. Prior to cleavage of the composition at X2, the composition acts as a promolecule that does not associate with cellular membranes to a significant or detectable level.Type: GrantFiled: September 11, 2017Date of Patent: May 12, 2020Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Michael Page, Charles S. Craik
-
Patent number: 10646594Abstract: A method of diagnosing a mitochondrial related disease in a subject includes administering a deuterated metabolic water precursor to the subject, measuring a rate of deuterated water formation in a sample region of the subject, and comparing the measured deuterated water formation in the sample region to a control value. A difference between the rate of deuterated water formation in the sample region compared to a control value is indicative of a mitochondrial related disease.Type: GrantFiled: June 21, 2010Date of Patent: May 12, 2020Assignee: CASE WESTERN RESERVE UNIVERSITYInventors: Jeffrey L. Duerk, Christopher A. Flask, Gheorghe D. Mateescu
-
Patent number: 10646595Abstract: Water soluble porphyrin compounds useful in the field of magnetic resonance imaging (MRI) as contrast agents. Particular compounds include manganese.Type: GrantFiled: February 12, 2013Date of Patent: May 12, 2020Assignees: THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO, THE HOSPITAL FOR SICK CHILDRENInventors: Xiao-an Zhang, Wei Ran Cheng, Inga Haedicke, Hai-Ling Cheng
-
Patent number: 10646596Abstract: A novel near-infrared dye-bound transferrin exhibiting a high absorption coefficient in the near-infrared wavelength region, a high tumor accumulation property, a high tumor/blood ratio and a high imaging contrast, and a contrast agent for photoacoustic imaging, including the same are provided. A compound is provided in which transferrin and an organic dye having a specified structure that absorbs light in the near-infrared wavelength region are covalently bound.Type: GrantFiled: March 15, 2016Date of Patent: May 12, 2020Assignee: CANON KABUSHIKI KAISHAInventors: Fumio Yamauchi, Kengo Kanazaki, Satoshi Ogawa
-
Patent number: 10646597Abstract: A coupling agent composition is provided and includes a plurality of non-toxic components and a thickening agent. The plurality of non-toxic components is derived from one or more natural resource materials and is an amount equal to or greater than 97 weight percent (wt %) of the composition. The thickening agent is provided in an amount of 0.05-5.00 wt % of the composition. The balance of the composition is incidental impurities.Type: GrantFiled: October 19, 2016Date of Patent: May 12, 2020Assignee: Wiesman Holdings, LLCInventors: Jon Wiesman, George Deckner
-
Patent number: 10646598Abstract: Disclosed is a class of versatile Sarcophagine based bifunctional chelators (BFCs) containing a hexa-aza cage for labeling with metals having either imaging, therapeutic or contrast applications radiolabeling and one or more linkers (A) and (B). The compounds have the general formula where A is a functional group selected from group consisting of an amine, a carboxylic acid, an ester, a carbonyl, a thiol, an azide and an alkene, and B is a functional group selected from the group consisting of hydrogen, an amine, a carboxylic acid, and ester, a carbonyl, a thiol, an azide and an alkene. Also disclosed are conjugate of the BFC and a targeting moiety, which may be a peptide or antibody. Also disclosed are metal complexes of the BFC/targeting moiety conjugates that are useful as radiopharmaceuticals, imaging agents or contrast agents.Type: GrantFiled: June 27, 2016Date of Patent: May 12, 2020Assignee: University of Southern CaliforniaInventors: Peter S. Conti, Hancheng Cai, Zibo Li, Shuanglong Liu
-
Patent number: 10646599Abstract: The present invention relates to radioimmunoconjugates that are capable of upregulating expression of one or more antigens. The upregulated antigens can be the antigens that are targeted by the radioimmunoconjugates or different antigens expressed on the same cells. The present invention also relates to methods of treating cancer and diseases and disorders of the immune system by utilizing this enhanced expression of antigens.Type: GrantFiled: June 13, 2018Date of Patent: May 12, 2020Assignee: NORDIC NANOVECTOR ASAInventors: Roy H. Larsen, Ada Repetto-Llamazares
-
Patent number: 10646600Abstract: A method of use of an isolated polypeptide conjugated with a radionuclide, wherein the isolated polypeptide binds specifically to HER2, or a variant thereof is described. The method is for monitoring the response to HSP90 inhibition and comprises the use of the isolated polypeptide conjugated with 18F. The application also describes the use of an isolated polypeptide conjugated with 18F, wherein the isolated polypeptide binds specifically to HER2 or variants thereof, as an imaging agent to monitor uptake thereof to measure HSP90 inhibition.Type: GrantFiled: June 24, 2014Date of Patent: May 12, 2020Assignees: IMPERIAL INNOVATIONS LIMITED, GE HEALTHCARE LIMITEDInventors: Duncan Robert R. Hiscock, Eric Aboagye, Peter Iveson, Quang-De Nguyen, Susan Hoppmann, Sebastian Trousil, Maciej Kaliszczak, Giampaolo Tomasi
-
Patent number: 10646601Abstract: A device for transferring a sterile product from one container to another under aseptic conditions. The first container to initially contain the sterile product and equipped with an outlet. The outlet has a first pipe and two independently operable valves mounted in series thereon. The second container is equipped with an inlet having a second pipe and two independently operable valves mounted in series thereon. A removable hose to provide a sealed connection of the free end of the first pipe and the free end of the second pipe. A connector to connect the removable hose to a system for sterilizing the internal volume thereof. The system is operable when the removable hose connects the free end of the first pipe with the free end of the second pipe in a sealed manner.Type: GrantFiled: January 22, 2015Date of Patent: May 12, 2020Assignee: PIERRE FABRE DERMO-COSMETIQUEInventors: Jean-Claude Delaunay, Laurent Serra
-
Patent number: 10646602Abstract: The present disclosure relates to sterilization methods and systems that may be used within numerous contexts, such as health-care and manufacturing facilities.Type: GrantFiled: November 3, 2006Date of Patent: May 12, 2020Assignee: Deep Science, LLCInventors: Edward K. Y. Jung, Royce A. Levien, Robert W. Lord, Mark A. Malamud, John D. Rinaldo, Jr., Lowell L. Wood, Jr.
-
Patent number: 10646603Abstract: Ultraviolet radiation is directed within an area. The target wavelength ranges and/or target intensity ranges of the ultraviolet radiation sources can correspond to at least one of a plurality of selectable operating configurations including a virus destruction operating configuration and a bacteria disinfection operating configuration. Each configuration can include a unique combination of the target wavelength range and target intensity range.Type: GrantFiled: March 30, 2018Date of Patent: May 12, 2020Assignee: Sensor Electronic Technology, Inc.Inventors: Michael Shur, Alexander Dobrinsky
-
Patent number: 10646604Abstract: Disclosed herein are flexible plasma applicators based on fibrous layers that are capable of rapidly sanitizing a surface via either direct or indirect contact with said surface.Type: GrantFiled: February 6, 2017Date of Patent: May 12, 2020Assignees: RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY, UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Aaron Mazzeo, Jingjin Xie, Qiang Chen, Subrata Roy
-
Patent number: 10646605Abstract: Embodiments of the invention relate to a method and apparatus for self-sterilizing a surface or other portion of the apparatus and/or sterilizing other objects. Embodiments can utilize self-generated and/or remotely controlled plasma fields for the purpose of self-sterilization and/or sterilization of another object. Embodiments of the invention can have broad applications in procedures and equipment requiring the sterility of devices used for medical procedures, decontamination procedures, drug delivery, sterility of consumer products, and sterility of food preparation equipment and tools.Type: GrantFiled: September 8, 2017Date of Patent: May 12, 2020Assignee: UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC.Inventors: Subrata Roy, Karl Zawoy
-
Patent number: 10646606Abstract: Systems and methods for dissolving ozone gas in a liquid. An embodiment can comprise a tank having an upper region, a lower region, and a discharge outlet, all disposed in a specified geometry. A pump can be coupled with a liquid inlet in order to receive a liquid therefrom and to deliver the liquid via a pipe to the upper region of the tank. The pump can be coupled with the lower region of the tank in order to receive the liquid from the tank and to recirculate the liquid to the upper region of the tank. The apparatus can include an ozone inlet to receive ozone into the tank. The ozone inlet can comprise a venturi inlet disposed on the pipe downstream of the pump. The liquid can be released from the tank and depressurized, thereby providing for the ozone to emerge from the liquid as gas bubbles. The released liquid can be selected for a two-stage gas and aqueous cleaning process.Type: GrantFiled: August 10, 2018Date of Patent: May 12, 2020Inventor: Lee C Ditzler
-
Patent number: 10646607Abstract: Activated hydrogen peroxide disinfecting compositions are provided especially for low-foaming applications. A concentrate for dilution by an end-user is provided, which includes a hydrogen peroxide source, a non-surfactant organic sulfonic acid or salt thereof, a non-ionic surfactant, and an optional organic acid. Also provided is a ready-to-use hydrogen peroxide, disinfectant solution including a biocidal amount of hydrogen peroxide, a non-surfactant organic sulfonic acid or salt thereof, a non-ionic surfactant, water as solvent and an optional organic acid. An end-user can disinfect a surface of microorganisms by contacting the surface with the disinfecting composition for an amount of time effective to kill a majority of the microbes located on the surface.Type: GrantFiled: September 17, 2015Date of Patent: May 12, 2020Assignee: Lonza, Inc.Inventors: Deqing Lei, Philip Gerdon Sweeny
-
Patent number: 10646608Abstract: In a system and method for disinfecting a surface of an object with iodine-laden gas, a carrier gas generation means generates a gas stream, which is then directed into a chamber that includes an iodine source. As the gas stream enters and passes through the chamber, iodine is drawn and absorbed into the gas stream, creating an iodine-laden gas that exits the chamber. In some embodiments, the iodine-laden gas then travels from the chamber and is directed into an enclosure when it interacts with microbes contained on a surface of an object housed within the enclosure or otherwise engaged by the enclosure. In other embodiments, as the iodine-laden gas exits the chamber, it is directed to a nozzle, via which the iodine-laden gas is applied to the surface of the object to be disinfected.Type: GrantFiled: October 8, 2019Date of Patent: May 12, 2020Assignee: i 2 Air Fluid Innovation, Inc.Inventor: Michael C. Radicone
-
Patent number: 10646609Abstract: Various implementations disclosed herein include a method for aiding disinfection of a room. The method may include collecting, by one or more sensors in a disinfection system, activity data in the room. A computing device or output device may identify one or more hot spots from the activity data, in which the one or more hot spots indicate areas in the room for cleaning, and generate a contamination map containing the one or more hot spots. The output device may output the contamination map to an output device for viewing by a user.Type: GrantFiled: October 20, 2017Date of Patent: May 12, 2020Assignee: OSRAM SYLVANIA Inc.Inventors: Joseph Olsen, Michael A. Quilici
-
Patent number: 10646610Abstract: An odor treatment dispenser is disclosed for an odor. The device comprises a housing having a canister channel. An aperture traverses the housing. A canister contains an odor treatment substance positioned within the canister channel. An actuator engages the canister for dispensing the odor treatment substance through the aperture for treating the odor.Type: GrantFiled: March 6, 2016Date of Patent: May 12, 2020Inventors: Jeffrey E. Tucker, Michael R. Thaler
-
Patent number: 10646611Abstract: Methods for contacting removing an odorous or noxious component from a gas stream using a scrubbing solution containing a biocide in a gas/liquid contactor are described. The biocide is used to avoid or prevent or minimize or control biological growth and fouling, particularly in the gas/liquid contactor.Type: GrantFiled: March 9, 2017Date of Patent: May 12, 2020Inventor: Stephen R. Temple
-
Patent number: 10646612Abstract: Provided is a water-absorbing agent which is less likely to cause gel blocking and is suitable for a sanitary product and an absorbent article each being thin and containing a large amount of a water-absorbing agent, and which, while maintaining or hardly losing the other physical properties (a fluid retention capacity and a bulk specific gravity) of the water-absorbing agent, simultaneously achieves a high water absorbing speed (e.g., FSR), a high fluid retention capacity under load, high liquid permeability, and salt tolerance. The water-absorbing agent is a polyacrylic acid (salt)-based water-absorbing agent whose surface and its vicinity are crosslinked by an organic surface crosslinking agent, characterized by satisfying the following (A)-(D): (A) Free Swell Rate (FSR) of at least 0.Type: GrantFiled: December 19, 2014Date of Patent: May 12, 2020Assignee: NIPPON SHOKUBAI CO., LTD.Inventors: Kohei Omori, Kazushi Torii, Nobuya Tanaka, Yusuke Watanabe
-
Patent number: 10646613Abstract: The present invention refers to a composition, comprising hemoglobin or myoglobin, wherein in at least 40% of said hemoglobin or myoglobin the oxygen binding site is charged by a non-O2 ligand, and at least one further ingredient, a method for preparing said composition and the use of hemoglobin or myoglobin charged with a non-oxygen ligand for external treatment of wounds.Type: GrantFiled: July 23, 2012Date of Patent: May 12, 2020Assignee: MÖLNLYCKE HEALTH CARE ABInventors: Michael Sander, Harald Potzschke
-
Patent number: 10646614Abstract: The inventions provided herein relate to dissolvable hydrogel compositions and methods of uses, e.g., but not limited to, in wound management. Accordingly, methods for wound management involving the dissolvable hydrogel compositions are also provided herein. In some embodiments, the dissolvable hydrogel composition comprises an adhesive thioester hydrogel, which can facilitate adherence of the dissolvable hydrogen composition to a surface (e.g., a wound) and can be controllably dissolved later upon addition of a thiolate compound to release the dissolvable hydrogel composition from the surface (e.g., the wound).Type: GrantFiled: May 9, 2018Date of Patent: May 12, 2020Assignee: TRUSTEES OF BOSTON UNIVERSITYInventors: Mark W. Grinstaff, Cynthia Ghobril, Michel Christophe Wathier, Marlena Dagmara Konieczynska
-
Patent number: 10646615Abstract: A biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material having a sintered CAP core and a closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core, wherein the closed epitactically grown layer of nanocrystalline HAP deposited on the external surface of the sintered CAP core has a homogeneous coarse external surface comprising flat crystal platelets, which shows an enhanced osteogenic response, a method of promoting bone formation, bone regeneration and/or bone repair by implanting the biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material, and a process of preparation thereof.Type: GrantFiled: September 25, 2019Date of Patent: May 12, 2020Assignee: Geistlich Pharma AGInventors: Claudio Zihlmann, Michael Bufler
-
Patent number: 10646616Abstract: A bone-regeneration material that contains calcium phosphate particles in biodegradable fibers of PLGA manufactured by electrospinning. A PLGA resin is heated in a kneader until the resin viscosity becomes 102 to 107 Pa·s. A powder of calcium phosphate fine particles is added while the blade is rotated. The mixture is kneaded by continuous rotation of the blade in the heated state to disperse the calcium phosphate fine particles to obtain a composite having calcium phosphate fine particles dispersed in the PLGA resin. The composite is dissolved by a solvent, and the PLGA resin is completely dissolved by agitation for a prescribed duration to prepare a spinning solution in which the calcium phosphate fine particles are dispersed. Electrospinning is performed on the spinning solution to manufacture biodegradable fibers having therein the calcium phosphate fine particles substantially uniformly dispersed.Type: GrantFiled: April 28, 2017Date of Patent: May 12, 2020Assignees: National University Corporation Nagoya Institute of Technology, Orthorebirth Co., Ltd.Inventors: Toshihiro Kasuga, Yasutoshi Nishikawa